The effectiveness of Mexidol in patients of different age groups with chronic brain ischemia with cognitive disorders (the results of subanalysis of the international multicenter randomized double blind placebo-controlled study of memes)

Authors:
V.V. Zakharov ¹ , O.N. Tkacheva ^{2, 3} , E.A. Mkhitaryan ^{2, 3} , A.I. Fedin ²

¹ FGAOU VO "First Moscow State Medical University named after THEM. Sechenov »Ministry of Health of Russia (Sechenov University), Moscow, Russia;
² FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia;
³ Russian gerontological scientific and clinical center of the FGAOU in the Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2022, T. 122, No. 11, Issue. 2

Summary:
Purpose of the study. To evaluate the effectiveness of consistent therapy with Mexidol and Mexidol Fort 250 compared to placebo in patients with chronic brain ischemia (chemical) of different age -related subgroups.

Material and methods. Subanalis of data of an international multicenter randomized double-centered placebo-controlled study of Memo, in which 318 patients (25% of men) aged 40 to 90 (median 60) years participated. The effectiveness of treatment was estimated in three age groups: 40-60 (n = 163), 61–75 (n = 141) and 76–90 (n = 13) years. As the primary final point of effectiveness, an increase in the dynamics of the amount of points on the MOCA scale in the form of an absolute difference between the amount of points before the start of treatment and on the 75th day of therapy was considered. As a secondary endpoint of efficiency, the speaker was considered the sum of the points on the following questionnaires and scales: a test for the replacement of digital characters, a questionnaire for the quality of life of the SF-36, the scale of the subjective assessment of asthenia MFI-20, the Vein’s autonomic questionnaire, the Bek anxiety scale, and the scale of motor activity of Tinetti .

Results. The positive dynamics of the severity of cognitive, emotional and motor disorders in groups 40-60 and 61–75 years after 75 days of therapy were detected in patients who received both Mexidol and placebo, however, in patients who received Mexidol, these changes were more pronounced, on What indicate the higher values ​​of the median of the absolute difference between the amount of points of the studied indicators.

Conclusion. The results of the study have shown that in patients with Khim, a significant improvement in cognitive and motor functions, improving the quality of life, a decrease in the severity of autonomic disorders, asthenia and anxiety after 75 days of therapy were observed against the background of the use of Mexido compared to placebo. The results indicate the appropriateness of the use of Mexidol for the treatment of patients of different ages with chemicals.

Keywords: cognitive disorders, chronic brain ischemia, Mexidol, Mexidol Fort 250, ethylmethylhydroxypyridine succinate, examination of memo.